- $234.07m
- -$84.67m
- $9.00m
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel
U.S. STOCKS ON THE MOVE-Autodesk, Teledyne, Alphabet
U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital
BioAge Labs edges down after stock sale hiked to $115 mln
Brief: Bioage Announces Pricing Of Upsized $115 Million Public Offering
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous
BioAge dips after unveiling planned $75 mln stock sale
Brief: Bioage Announces Proposed Public Offering
Brief: Bioage Announces Additional Positive Interim Phase 1 Data For BGE-102, A Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential For Best-In-Class Hscrp Reduction In Participants With Elevated Cardiovascular Risk
Brief: Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102
U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic
Brief: BioAge Labs Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing